Health Condition 1: null- Patients with genital/venereal warts
Conditions
Interventions
Intervention1: Tablet levamisol 150 mg oral tablet: Intervention arm would be given tablet levamisol 150 mg on two consecutive days in a week for 12 weeks in addition to the standard treatment in a d
Sponsors
Dr RML Hospital New Delhi
Department of Transplant ImmunologyAIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with anogenital warts who have not received any topical treatment in last 4 weeks and any systemic therapy in last 12 weeks 2. Patients who are willing to give informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant females 2. Extensive warts 3. Any topical treatment in last 4 weeks 4. Any systemic therapy in last 12 weeks 5. Giant condyloma acuminate 6. Immunocompromised patients including HIV positivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Rate of the clinical improvement and the immunological parameters mentioned below. 1 The increase in Th1cytokines (IFN gamma) is likely to be associated with decreased relapse. 2. Increase in the Th2 cytokines (IL 4 and IL 10) is likely to be associated with delayed therapeutic response and /or relapse. 3 T reg parameters Timepoint: Clinical evaluation at 4 weeks 8 weeks 12 weeks 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction / prevention of relapseTimepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactDr H K Kar
ICMR
Outcome results
None listed